Gout

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pay $40 million upfront for global rights to Arrowhead Pharmaceuticals...

Selecta Biosciences Inc (NASDAQ: SELB) shares plummeted in November 2017 from the $20 level and have yet to recover. The stock should not only recoup all of its losses, but trade at new all-time highs, according to Janney.  The Analyst Janney's Yun Zhong initiated coverage of Selecta...